Cargando…
Medical therapy doses at hospital discharge in patients with existing and de novo heart failure
AIMS: Uptitrating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ACE‐I/ARBs), beta‐blockers, and mineralocorticoid receptor antagonists (MRAs) to optimal doses in heart failure with reduced ejection fraction (HFrEF) is associated with improved outcomes and recommended in...
Autores principales: | Diamant, Michael J., Virani, Sean A., MacKenzie, Winston J., Ignaszewski, Andrew, Toma, Mustafa, Hawkins, Nathaniel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676447/ https://www.ncbi.nlm.nih.gov/pubmed/31218850 http://dx.doi.org/10.1002/ehf2.12454 |
Ejemplares similares
-
Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure
por: Osmanska, Joanna, et al.
Publicado: (2018) -
Heart failure and atrial flutter: a systematic review of current knowledge and practices
por: Diamant, Michael J., et al.
Publicado: (2021) -
Epidemiology and treatment of heart failure with chronic obstructive pulmonary disease in Canadian primary care
por: Hawkins, Nathaniel M., et al.
Publicado: (2023) -
Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines
por: MacDonald, Blair J., et al.
Publicado: (2023) -
The Canadian Heart Failure (CAN-HF) Registry: A Canadian Multicentre, Retrospective Study of Inpatients With Heart Failure
por: Poon, Stephanie, et al.
Publicado: (2022)